文献速递胸部神经MR

MRI影像组学预测EGFR突变非小细胞肺癌脑转移患者EGFR-TKI疗效

MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis.
PubMed 文献 · Clin Radiol · 2024-03-19

本研究纳入2014年1月1日至2021年12月31日接受EGFR-TKI治疗的117例EGFR突变非小细胞肺癌脑转移患者,按2:1随机分为训练集和验证集,基于脑MRI提取影像组学特征构建临床、影像组学及联合列线图,预测短期疗效和颅内无进展生存期;联合列线图预测短期疗效的训练集和验证集C-index分别为0.860和0.843,预测iPFS分别为0.837和0.850,均优于单一列线图。

要点

  • 联合列线图预测短期疗效的训练集C-index为0.860(95%CI 0.820-0.901),验证集为0.843(95%CI 0.783-0.904)。
  • 联合列线图预测iPFS的训练集C-index为0.837(95%CI 0.751-0.923),验证集为0.850(95%CI 0.763-0.937)。
  • 联合列线图预测EGFR-TKI疗效优于单一临床或影像组学列线图。

核心结论

  • 联合列线图在预测EGFR突变非小细胞肺癌脑转移患者EGFR-TKI疗效方面比单一临床或影像组学列线图更有效。

研究设计与样本

  • 回顾性研究,纳入117例接受EGFR-TKI治疗的EGFR突变非小细胞肺癌脑转移患者,按2:1随机分为训练集和验证集,基于脑MRI提取影像组学特征,采用LASSO算法筛选特征,逻辑回归和Cox比例风险回归筛选临床危险因素,构建临床、影像组学及联合列线图。

诊断标准与关键数值

  • 短期疗效模型联合列线图训练集C-index为0.860(95%CI 0.820-0.901),验证集为0.843(95%CI 0.783-0.904)。
  • iPFS模型联合列线图训练集C-index为0.837(95%CI 0.751-0.923),验证集为0.850(95%CI 0.763-0.937)。
  • 总体缓解率为57.3%,中位iPFS为12.67个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To develop and validate models based on magnetic resonance imaging (MRI) radiomics for predicting the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients with brain metastases.

MATERIALS AND METHODS: 117 EGFR-mutant NSCLC patients with brain metastases who received EGFR-TKI treatment were included in this study from January 1, 2014 to December 31, 2021. Patients were randomly divided into training and validation cohorts in a ratio of 2:1. Radiomics features extracted from brain MRI were screened by least absolute shrinkage and selection operator (LASSO) algorithm. Logistic regression analysis and Cox proportional hazard regression analysis were used to screen clinical risk factors. Clinical (C), radiomics (R), and combined (C + R) nomograms were constructed in models predicting short-term efficacy and intracranial progression-free survival (iPFS), respectively. Calibration curves, Harrell's concordance index (C-index), and decision curve analysis (DCA) were used to evaluate the performance of models.

RESULTS: Overall response rate (ORR) was 57.3% and median iPFS was 12.67 months. The C + R nomograms were more effective. In the short-term efficacy model, the C-indexes of C + R nomograms in training cohort and validation cohort were 0.860 (0.820-0.901, 95%CI) and 0.843 (0.783-0.904, 95%CI). In iPFS model, the C-indexes of C + R nomograms in training cohort and validation cohort were 0.837 (0.751-0.923, 95%CI) and 0.850 (0.763-0.937, 95%CI).

CONCLUSION: The C + R nomograms were more effective in predicting EGFR-TKI efficacy of EGFR-mutant NSCLC patients with brain metastases than single clinical or radiomics nomograms.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Qi H, Hou Y, Zheng Z, et al. MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis. Clin Radiol. 2024. PMID: 38637187. doi:10.1016/j.crad.2024.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。